Sign in

CIK 0001438533 · Large accelerated filer

Travere Therapeutics, Inc.

Sign in to watch
Ticker
TVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
CA
Entity type
operating
EIN
262383102
Phone
888-969-7879
Business address
3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
Former names
Retrophin, Inc., Desert Gateway, Inc.
  1. 4 Grant or award Director acquired 3,000 shares (grant or award)
  2. 4 Grant or award Director acquired 3,000 shares (grant or award)
  3. 4 Grant or award Director acquired 3,000 shares (grant or award)
  4. 4 Grant or award Director acquired 3,000 shares (grant or award)
  5. 4 Grant or award Director acquired 3,000 shares (grant or award)
  6. 4 Grant or award Director acquired 3,000 shares (grant or award)
  7. 4 Grant or award Director acquired 3,000 shares (grant or award)
  8. 4 Grant or award Director acquired 3,000 shares (grant or award)
  9. 4 Grant or award Director acquired 3,000 shares (grant or award)
  10. 4 Open-market sale Senior Vice President, R&D sold 3,125 shares at an average $19.30 ($60,312)
  11. 4 Open-market sale Chief Medical Officer sold 750 shares at an average $19.30 ($14,475)
  12. 4 Open-market sale SVP, GC & Corporate Secretary sold 3,250 shares at an average $19.30 ($62,725)
  13. 4 Open-market sale Chief Financial Officer sold 4,000 shares at an average $19.30 ($77,200)
  14. 4 Open-market sale Director sold 2,146 shares at $19.58 ($42,023)
  15. 10-Q Report Quarterly Report
  16. 8-K Event Results of operations
  17. 4 Open-market sale Director sold 10,000 shares at $26.23 ($262,300)
  18. DEF 14A Proxy Proxy Statement
  19. PRE 14A Proxy Proxy Statement (Preliminary)
  20. 4 Open-market sale Director sold 17,727 shares at an average $27.44 ($486,456)

Page 30 of 65 · 1,286 filings